Mizuho Securities Keeps a Buy Rating on Atara Biotherapeutics (ATRA)

In a report released yesterday, Salim Syed from Mizuho Securities maintained a Buy rating on Atara Biotherapeutics (ATRAResearch Report), with a price target of $41.00. The company’s shares closed last Monday at $12.85, close to its 52-week low of $11.50.

According to TipRanks.com, Syed has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.3% and a 35.8% success rate. Syed covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Unity Biotechnology, and BridgeBio Pharma.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atara Biotherapeutics with a $31.00 average price target, representing a 136.5% upside. In a report issued on February 18, Stifel Nicolaus also reiterated a Buy rating on the stock with a $25.00 price target.

See the top stocks recommended by analysts >>

Atara Biotherapeutics’ market cap is currently $1.17B and has a P/E ratio of -3.64.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Read More on ATRA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More